Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 4Thyroid Carcinoma, Anaplastic 3Neoplasms 3Glioma 3Recurrence 2Neurofibromatosis 1 2Neoplasm Metastasis 2Multiple Myeloma 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Thyroid Neoplasms 1Solid Tumor Cancer 1Solid Tumor 1Skin Neoplasms 1Sexual Dysfunction, Physiological 1Refractory Differentiated Thyroid Gland Carcinoma 1Rare Malignant Neoplasm 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Oligodendroglioma 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Leukemia, Myelomonocytic, Juvenile 1

Interventions

Injections 16pembrolizumab 6Bevacizumab 6Paclitaxel 4Leucovorin 4Fluorouracil 4Carboplatin 4fludarabine 3Pemetrexed 3Oxaliplatin 3Capecitabine 3toripalimab 2sotorasib 2Immune Checkpoint Inhibitors 2Fulvestrant 2Drug Therapy 2Docetaxel 2Cyclophosphamide 2Cisplatin 2130-nm albumin-bound paclitaxel 2zimberelimab 1trifluridine tipiracil drug combination 1trametinib 1tislelizumab 1sacituzumab govitecan 1palbociclib 1osimertinib 1olaparib 1lazertinib 1fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Solid Tumors × trametinib × Clear all
NCT06804824 2026-03-18

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

Vividion Therapeutics, Inc.

Phase 1 Recruiting
220 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡